Ethic Inc. Purchases 5,198 Shares of Zoetis Inc. $ZTS

Ethic Inc. increased its position in shares of Zoetis Inc. (NYSE:ZTS) by 10.8% during the 2nd quarter, Holdings Channel reports. The fund owned 53,253 shares of the company’s stock after buying an additional 5,198 shares during the quarter. Ethic Inc.’s holdings in Zoetis were worth $8,317,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Nova Wealth Management Inc. bought a new position in Zoetis during the 1st quarter worth approximately $25,000. 1248 Management LLC bought a new position in Zoetis in the first quarter valued at approximately $27,000. Saudi Central Bank bought a new position in Zoetis in the first quarter valued at approximately $29,000. Cornerstone Planning Group LLC lifted its stake in Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after buying an additional 88 shares in the last quarter. Finally, REAP Financial Group LLC lifted its stake in Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after buying an additional 131 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. UBS Group cut their price target on shares of Zoetis from $165.00 to $158.00 and set a “neutral” rating on the stock in a research note on Monday. Piper Sandler lifted their price target on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and cut their price target for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Argus reaffirmed a “buy” rating and issued a $190.00 price target on shares of Zoetis in a research note on Tuesday, September 9th. Finally, Leerink Partnrs lowered shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Four investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, Zoetis currently has an average rating of “Hold” and an average target price of $195.00.

Zoetis Stock Performance

Shares of ZTS stock opened at $147.10 on Thursday. The company’s fifty day simple moving average is $148.47 and its 200-day simple moving average is $153.51. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The firm has a market cap of $65.19 billion, a PE ratio of 25.32, a P/E/G ratio of 2.35 and a beta of 0.90. Zoetis Inc. has a 12 month low of $139.34 and a 12 month high of $189.98.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. The business had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s payout ratio is currently 34.42%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.